

AMENDMENTS TO THE CLAIMS

Claims 1 - 10. (canceled)

Claim 11 (Currently Amended): ~~A pharmaceutical composition~~ An aerosol formulation comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide, and wherein said propellant is one or more hydrofluoralkanes.

Claim 12 (Previously Presented): The pharmaceutical composition of claim 11, wherein said antioxidant is ascorbyl palmitate.

Claim 13 (Previously Presented): The pharmaceutical composition of claim 11, wherein said antioxidant is a tocopherol ester.

Claim 14 (Previously Presented): The pharmaceutical composition of claim 11, wherein said antioxidant is selected from the group consisting of ascorbic acid, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and tocopherol esters.

Claim 15 (Previously Presented): The pharmaceutical composition of claim 11, wherein the corticosteroid is budesonide.

Claim 16 (Previously Presented): The pharmaceutical composition of claim 11, wherein the propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane, or a mixture thereof.

Claim 17 (Previously Presented): The pharmaceutical composition of claim 11, wherein said cosolvent is an alcohol.

Claim 18 (Previously Presented): The pharmaceutical composition of claim 17, wherein said alcohol is ethanol.

Claim 19 (Currently Amended): A pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising

a corticosteroid, a propellant, a cosolvent, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide, and wherein said propellant is one or more hydrofluoralkanes.

Claim 20 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein the corticosteroid is budesonide.

Claim 21 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or a mixture thereof.

Claim 22 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said cosolvent is an alcohol.

Claim 23 (Previously Presented): The pressurized metered dose inhaler according to claim 22, wherein said alcohol is ethanol.

Claim 24 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said antioxidant is ascorbyl palmitate.

Claim 25 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said antioxidant is a tocopherol ester.

Claim 26 (Currently Amended): A method for the treatment of a bronchial disorder comprising administering a pharmaceutical an aerosol formulation comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide, and wherein said propellant is one or more hydrofluoralkanes.

Claim 27 (Previously Presented): The method according to claim 26, wherein said corticosteroid is budesonide.

Claim 28 (Previously Presented): The method according to claim 26, wherein said propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane or a mixture thereof.

Claim 29 (Previously Presented): The method according to claim 26, wherein said cosolvent is an alcohol.

Claim 30 (Previously Presented): The method according to claim 29, wherein said alcohol is ethanol.

Claim 31 (Previously Presented): The method according to claim 26, wherein said antioxidant is ascorbyl palmitate.

Claim 32 (Previously Presented): The method according to claim 26, wherein said antioxidant is a tocopherol ester.

SUPPORT FOR THE AMENDMENTS

Claims 1-10 were previously canceled.

Claims 11, 19, and 26 have been amended.

Support for the amendment of Claims 11, 19, and 26 is provided by page 1, lines 3-8, page 1, lines 12-16, page 1, lines 19-21, page 4, lines 27-28, and the Examples.

No new matter is believed to have been added by these amendments.